Table 1:
Demographics and clinical characteristics of PV patients
| Variable | Overall (n = 470) | PHL (n = 133) | IFN (n = 93) | HU (n = 189) | Other (n = 55) | P |
|---|---|---|---|---|---|---|
| Age (years), median (range) | 54 (20–94) | 54 (20–94) | 50 (26–82) | 58 (22–84) | 52 (20–91) | <0.001 * |
| Sex: female, n (%) | 229 (49) | 55 (41) | 43 (46) | 102 (54) | 29 (53) | 0.14 |
| Race, n evaluable = 404, n (%) | 0.13 | |||||
| White | 361 (86) | 99 (88) | 81 (93) | 141 (82) | 40 (83) | |
| Asian, Black or Hispanic | 43 (10) | 11 (10) | 4 (5) | 24 (14) | 4 (8) | |
| Other minority | 15 (4) | 3 (3) | 2 (2) | 6 (4) | 4 (8) | |
| Cardiovascular (CV) risk factors, n (%) | 101 (21) | 13 (10) | 25 (27) | 50 (26) | 13 (24) | 0.002 * |
| Thrombosis history, n (%) | 65 (14) | 15 (11) | 11 (12) | 31 (16) | 8 (15) | 0.55 |
| ELN risk: high, n (%) | 208 (44) | 56 (42) | 22 (24) | 105 (56) | 25 (45) | <0.001 * |
| JAK2V617F positive, n evaluable = 361, n (%) | 355 (98) | 76 (96) | 83 (99) | 151 (99) | 45 (100) | 0.36 |
| Cytogenetic risk, n evaluable = 231, n (%) | 0.04 | |||||
| Low | 207 (90) | 46 (88) | 60 (95) | 79 (85) | 22 (96) | |
| Intermediate | 18 (8) | 2 (4) | 3 (5) | 12 (13) | 1 (4) | |
| High | 6 (3) | 4 (8) | 0 (0) | 2 (2) | 0 (0) | |
| Co-occurrent mutations present, n evaluable = 105, n (%) | 51 (49) | 12 (55) | 11 (37) | 20 (62) | 8 (38) | 0.14 |
| Diagnosis date (year), median (range) | 2005 (1966–2019) | 2008 (1986–2019) | 2005 (1982–2019) | 2004 (1966–2018) | 2004 (1986–2018) | 0.009 * |
| Follow-up duration (years), median (range) | 10 (0–45) | 5 (0–32) | 13 (1–35) | 11 (0–45) | 9 (1–32) | <0.001 |
| Time to cytoreductive treatment (years), median (range) | 1 (0–30) | NA | 1 (0–15) | 1 (0–26) | 1 (0–30) | 0.21 |
| Treatment start (year), median (range) | 2008 (1982–2019) | 2008 (1986–2019) | 2009 (1982–2019) | 2007 (1983–2019) | 2008 (1997–2019) | 0.39 |
| Treatment duration (years), median (range) | 4 (0–28) | 4 (0–28) | 5 (1–26) | 5 (0–26) | 3 (1–15) | 0.005 * |
*
p-values comparing IFN to PHL, IFN to HU, HU to PHL by:
Age = 0.006, <0.001, 0.01
ELN risk = 0.006, <0.001, 0.02
CV risk factors = 0.001, ns, <0.001
Diagnosis date = 0.01, ns, 0.001
Treatment duration = ns, ns, ns